论文部分内容阅读
邦解清,化学名为盐酸噻氯匹定(Ticlopidine Hy-drochloride.TP),1978年由法国赛诺菲公司首先研制并上市,1993年被收入法国药典,商品名为抵克力得,1995年国产品也用于临床。TP作为新一代抗血小板聚集药,抗凝效果优于阿斯匹林、潘生丁。一、作用机制 纤维蛋白原受体暴露导致血小板相互聚集,TP可在体外和体内抑制ADP诱导的血小板聚集,另外TP对大鼠和家兔血小板细胞内贮存Ca~(++)的动员有作用,同时抑制膜的信息传递(从ADP受体到纤维蛋白
State to clear, the chemical name of ticlopidine hydrochloride (Ticlopidine Hy-drochloride.TP), first developed by the French company Sanofi in 1978 and listed in 1993 was the French Pharmacopoeia, the trade name of Tim grams, 1995 National products are also used in clinical. TP as a new generation of anti-platelet aggregation drug, anticoagulant effect is better than aspirin, dipyridamole. First, the mechanism of action fibrinogen receptor exposure led to the aggregation of platelets, TP in vitro and in vivo inhibition of ADP-induced platelet aggregation, the other TP and rat platelet intracellular storage of Ca ~ (++) mobilization have a role , While inhibiting membrane signaling (from ADP receptors to fibrin